<DOC>
	<DOCNO>NCT00788125</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . Drugs chemotherapy , ifosfamide , carboplatin , etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving dasatinib together ifosfamide , carboplatin , etoposide may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose dasatinib give together ifosfamide , carboplatin , etoposide see well work treat young patient metastatic recurrent malignant solid tumor .</brief_summary>
	<brief_title>Dasatinib , Ifosfamide , Carboplatin , Etoposide Treating Young Patients With Metastatic Recurrent Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose ( MTD ) dasatinib give immediately follow ifosfamide , carboplatin , etoposide phosphate ( D-ICE ) re-induction regimen young patient metastatic recurrent malignant solid tumor . ( Phase I ) - To describe define toxicity D-ICE patient . ( Phase I ) - To determine safety feasibility prolonged administration single-agent dasatinib follow completion 2-6 course D-ICE patient . ( Phase I ) - To estimate overall survival , progression-free survival , time progression patient treat D-ICE MTD follow single-agent dasatinib . ( Phase II ) - To estimate response rate two course D-ICE give MTD patient . ( Phase II ) Secondary - To determine phosphotyrosine state SRC family kinase related signal pathway , include FAK , STAT3 , VEGFR , AKT , EGFR , KIT , EPHA2 , PDGFR , paraffin-embedded tumor sample measure immunohistochemistry prior treatment dasatinib . - To assess gene expression profile fresh frozen tissue sample measure microarray analysis ( Affymetrix GeneChips ) baseline identify molecular signature may predict response dasatinib . - To correlate biomarkers molecular signature dasatinib dosage , toxicity , antitumor activity . - To evaluate effect dasatinib phosphorylation SRC family kinases peripheral blood mononuclear cell sample surrogate marker response prior treatment dasatinib , day 14-21 WBC ≥ 500/μL , treatment course , time local control , time progression . OUTLINE : This multicenter , phase I , dose-escalation study dasatinib follow phase II study . Patients enrol phase II stratify accord disease . Patients receive D-ICE comprise oral dasatinib twice daily day 5-21 , ifosfamide IV 1 hour etoposide phosphate IV 1 hour day 1-5 , carboplatin IV 1 hour day 1 2 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo radiotherapy and/or surgery ( consolidation therapy ) 2 , 4 , 6 course D-ICE . After completion consolidation therapy , patient receive oral dasatinib twice daily 6 month absence disease progression unacceptable toxicity . Tumor tissue peripheral blood mononuclear cell ( PBMC ) sample collect periodically correlative laboratory study . PBMCs analyze western blot total phospho-SRC , phospho-FAK , relevant biomarkers . Tumor tissue sample analyze IHC total phospho-SRC , phospho-FAK , phospho-STAT3 , phospho-KIT , phospho-PDGFR , EPHA2 , VEGF . Tumor tissue sample also analyze microarray gene expression profile define potential molecular signature gene expression pattern may predict response dasatinib . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor respond relapse standard firstline chemotherapy antineoplastic therapy ( standard therapy tumor generally recognize beneficial ) Must initially diagnose malignancy prior 25 year age Radiographic , nuclear image , biopsy confirmation disease within past 4 week Meets one follow criterion : Phase I : Relapsed/refractory malignant solid tumor ( exclude CNS tumor ) Patients recurrent metastatic disease completely resect prior study entry eligible Phase II : Patients stratify accord one follow diagnosis : Stratum A : Relapsed sarcoma ( rhabdomyosarcoma , osteosarcoma , Ewing sarcoma ) Stratum B : Other relapse solid tumor , include following : Other soft tissue sarcomas Kidney tumor Lymphoma CNS tumors* Other solid tumor ( neuroblastoma , gonadal germ cell tumor , liver tumor , miscellaneous tumor ) Stratum C : Newly diagnose , poorrisk metastatic sarcoma consist unresectable pulmonary metastasis ( ≥ 6 nodule ) and/or disease involve multiple bone organ NOTE : *Patients recurrent primary CNS tumor eligible phase II portion study provide significant intratumoral bleeding toxicity see either COG pediatric phase I study dasatinib phase I portion study Radiographically measurable disease ( Phase II ) Measurable disease require patient enrolled phase I portion study No bone marrow involvement ( Phase I ) Patients bone marrow involvement eligible phase II portion study provide known refractory red cell platelet transfusion PATIENT CHARACTERISTICS : Lansky performance status ( PS ) 50100 % ( patient 116 year age ) Karnofsky PS 50100 % ( patient &gt; 16 year age ) Life expectancy ≥ 8 week ANC &gt; 1,000/μL Platelet count &gt; 75,000/μL Creatinine clearance GFR ≥ 70 mL/min OR creatinine &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN age SGOT SGPT &lt; 2.5 time ULN age ( &lt; 5 time ULN liver involvement tumor ) Ejection fraction normal MUGA OR shorten fraction &gt; 28 % No evidence cardiac arrhythmia require therapy Corrected QTc interval &lt; 450 msec Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able comply safety monitoring requirement study No uncontrolled infection No swallowing dysfunction would preclude oral medication intake Gastric jejunal tube allow provide function No history significant bleeding disorder unrelated cancer , include follow : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Acquired bleed disorder diagnose within past year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( within past 3 month ) significant gastrointestinal bleeding PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 7 day since prior concurrent drug know cause Torsades de Pointes , include follow : Procainamide disopyramide Amiodarone , sotalol , ibutilide , dofetilide Erythromycin clarithromycin Chlorpromazine , haloperidol , mesoridazine , thioridazine Bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine At least 3 week since prior chemotherapy ( 6 week nitrosoureacontaining therapy ) At least 3 month since prior ifosfamide , carboplatin , and/or etoposide phosphate exact combination dosage administer study More 7 day since prior filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin11 More 14 day since prior pegfilgrastim More 30 day since prior epoetin alfa No prior cranialspinal irradiation dose &gt; 2,400 cGy No prior radiotherapy , include totalbody irradiation , &gt; 50 % bone marrow space No concurrent investigational drug anticancer agent No concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin , phenobarbital , felbamate , primdone , oxcarbazepine , carbamazepine ) No concurrent antithrombotic antiplatelet agent ( e.g. , warfarin , heparin , low molecular weight heparin , aspirin , ibuprofen , NSAIDs ) No concurrent CYP3A4 inhibitor ( e.g. , itraconazole , ketoconazole , voriconazole ) No concurrent highly active antiretroviral therapy HIVpositive patient No concurrent St. John 's wort No IV bisphosphonates first 8 week dasatinib therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>childhood extracranial germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>childhood renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>congenital mesoblastic nephroma</keyword>
	<keyword>cystic nephroma</keyword>
	<keyword>peripheral primitive neuroectodermal tumor kidney</keyword>
	<keyword>rhabdoid tumor kidney</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>childhood central nervous system choriocarcinoma</keyword>
	<keyword>childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood central nervous system germinoma</keyword>
	<keyword>childhood central nervous system mixed germ cell tumor</keyword>
	<keyword>childhood central nervous system teratoma</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
	<keyword>recurrent childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood ependymoblastoma</keyword>
	<keyword>childhood medulloepithelioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood pineal parenchymal tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood spinal cord neoplasm</keyword>
</DOC>